Presentation is loading. Please wait.

Presentation is loading. Please wait.

Proteasome-ubiquitin pathway in pathology Nikolajs Sjakste, Faculty of Medicine, University of Latvia Genetic and Environmental Influence of Bronchial.

Similar presentations


Presentation on theme: "Proteasome-ubiquitin pathway in pathology Nikolajs Sjakste, Faculty of Medicine, University of Latvia Genetic and Environmental Influence of Bronchial."— Presentation transcript:

1 Proteasome-ubiquitin pathway in pathology Nikolajs Sjakste, Faculty of Medicine, University of Latvia Genetic and Environmental Influence of Bronchial Asthma in Taiwan, Latvia and Lithuania, Tainan,

2 Proteasomes

3

4 How the proteasome acts

5

6

7

8

9 “E3-diseases” There is only one E1 enzyme About 10 E2 enzymes 1000 E3 enzymes E3 enzymes are divided in 3 classes RING U-box HECT-domain E3 ligases

10 What happens if a E3 enzyme gene of the proteasome-ubiquitin system gene is completely deleted? Subtelomeric region of Chromosome 15 harbours UBE3A gene which encodes Ubiquitin-protein ligase E3A (UBE3A)

11 Inheritance of the deletion from the mother on chromosome 15 produces Angelman syndrome

12 AS is characterized by intellectual and developmental delay, speech impediment, sleep disturbance, unstable jerky gait, seizures, hand flapping movements, frequent laughter/smiling and usually a happy demeanour. AS is a classic example of genetic imprinting caused by deletion or inactivation of critical genes on the maternally inherited chromosome 15. developmental delay seizures imprinting chromosome 15

13 Angelman syndrome can also be the result of mutation of a single gene. This gene (Ube3a) part of the ubiquitin pathway) is present on both the maternal and paternal chromosomes, but differs in the pattern of methylation (Imprinting). The paternal silencing of the Ube3a gene occurs in a brain region-specific manner; the maternal allele is active almost exclusively in the hippocampus and cerebellum. The most common genetic defect leading to Angelman syndrome is an ~4Mb (mega base) maternal deletion in chromosomal region 15q11-13 causing an absence of Ube3a expression in the maternally imprinted brain regions. Ube3a codes for an E6-AP ubiquitin ligase, which chooses its substrates very selectively and the four identified E6-AP substrates have shed little light on the possible molecular mechanisms underlying the human Angelman syndrome mental retardation state.Ube3aubiquitinmethylationImprinting hippocampuscerebellumubiquitin ligase

14 E3 neurodevelopmental diseases DiseaseUPS component affected Function Angelman syndromeUBE3AE3 ligase Williams-Beuren syndromeTRIM50E3 ligase Intellectual disability not otherwise specified CUL4BE3 ligase HUWE1E3 ligase. Suppresses N-Myc-DLl3 cascade, stops proliferation enables neuronal differentiation

15 A girl with Williams syndrome, illustrating typical facial features: broad forehead, short palpebral fissures, low nasal bridge, anteverted nostrils, long filtrum, full cheeks, and relatively large and often downturned mouth

16 E3 neurodevelopmental diseases 2 Autism spectrum disorders UBE3AE3 ligase PARK2E3 ligase RFWD2E3 ligase FBXO40Constitutes one of the four subunits of the ubiquitin protein ligase complex called SCFs (SKP1-cullin-F-box), Johanson-Blizzard syndrome UBR1E3 ligase

17 Johanson-Blizzard syndrome Ectodermal displasia : Abnormal development of the pancreas Nose Scalp Mental retardaton Hearing loss Growth failure

18 E3 neurodegenerative diseases Parkinson diseaseParkin (PARK2) E3-ligase Machado-Joseph disease ATXN3 Ataxin-3 interacts with ubiquitinated proteins, can bind the proteasome, when the gene harbors an expanded repeat length, can interfere with the degradation substrates. Associates with the ubiquitin- and proteasome-binding factors Rad23 and valosin-containing protein (VCP/p97). proteins.

19 E3 in inherited cancer syndromes Von Hippel-Lindau syndrome Adenomatous polyposis coli

20 Von Hippel-Lindau syndrome pVHL is an E3 ligase

21 Deubiqitination diseases DiseaseUPS component affected Function AtaxiaUSP-14Ubiquitin carboxyl- terminal hydrolase 14 Parkinson disease UCH-L1 (PARK5) Ubiquitin carboxy- terminal hydrolase L1

22 Immunoproteasomes IFN-gamma induces the synthesis of three active site−containing beta-subunits as well as the synthesis of the proteasome maturation protein (POMP). The immunosubunits 1i, 2i and 5i are preferentially incorporated into the 20S core after de novo synthesis to form the immunoproteasome. In addition, IFN-gamma induces synthesis of PA28. Three PA28 and four P28 subunits form heptameric rings that can bind to the two outer alpha-rings of the 20S constitutive proteasome as well as the 20S immunoproteasome and activate the enzyme complex by opening the central gate.

23 Immunoproteasomes

24

25

26 “Immunoproteasome” diseases Nakajo-Nishimura syndrome JMP syndrome CANDLE syndrome

27 Nakajo-Nishimura syndrome an autoinflammatory disorder pernio-like rashes progressive partial lipodystrophy homozygous mutation c.224C > T in exon 2 the PSMB8 gene, which encodes the β5i subunit of immunoproteasome is responsible for development of the disease

28

29

30 JMP syndrome Recessive autoinflammatory syndrome characterized by joint contractures, muscle atrophy, microcytic anemia, and panniculitis- induced lipodystrophy (JMP) Caused by homozygous missense mutation c.224C>T (p.Thr75Met) in the PSMB8

31 CANDLE syndrome Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature is an autoinflammatory syndrome recently described in children.

32 CANDLE syndrome is caused by mutations in PSMB8 One patient was homozygous for a novel nonsense mutation in PSMB8 (c.405C>A), suggesting a protein truncation; 4 patients were homozygous and 2 were heterozygous for a previously reported missense mutation (c.224C>T)

33

34 Pathologies of “bad substrates” for proteasomes

35 Polyglutamine (PolyQ) Diseases DiseaseGeneNormal number of repeats Pathologic number of repeats DRPLA (Dentatoru bropallidolu ysian atrophy)Dentatoru bropallidolu ysian atrophy ATN1ATN1 or DRPLA between 6 and 35 copies of CAG between 49 and 88 copies

36 Polyglutamine (PolyQ) Diseases 2 HD (Huntington's disease)Huntington's disease HDbetween 10 and 35 copies of CAG more than 35 copies SBMA (Spinobulb ar muscular atrophy or Kennedy disease)Spinobulb ar muscular atrophy Kennedy disease ARAR - Androgen receptor on the X chromosom e Androgen receptorX chromosom e between 9 and 36 copies of CAG between 38 and 62 copies

37 Models of Poly Q diseases Aggregation-prone proteins Amyloid formation Insoluble aggregates Silica NPs

38 Liddle syndrome severe hypertension, hypokalemia, and metabolic alkalosis. In contrast to hyperaldosteronism, which can result in similar symptoms, low aldosterone and renin levels

39 The gene responsible for Liddle syndrome was actually identified as a mutation in the beta subunit of the renal epithelial sodium channel (ENaC). The site of the mutation is located in its binding site to Nedd4 (E3 ubiquitin ligase). Because Nedd4 cannot recognize the channel and target it for degradation,it accumulates. Thus, the mutation leads to excessive re-absorption of Na+ accompanied by water.

40 Alzheimer’s disease Mutated ubiquitin Impaired proteasome function More immunoproteasomes

41

42 Ubiquitination sites on amino terminally processed tau. Ihara Y et al. Cold Spring Harb Perspect Med 2012;2:a ©2012 by Cold Spring Harbor Laboratory Press

43 Dysfunction of autophagic and endocytic pathways to lysosomes driven by relevant genes and other risk factors in Alzheimer disease (left side of the diagram) causes or promotes pathophysiology critical to the development and progression of Alzheimer disease... Ihara Y et al. Cold Spring Harb Perspect Med 2012;2:a ©2012 by Cold Spring Harbor Laboratory Press

44 Schematic illustrating the endocytic and the autophagic pathways to the lysosome. Ihara Y et al. Cold Spring Harb Perspect Med 2012;2:a ©2012 by Cold Spring Harbor Laboratory Press

45 Frontotemporal dementias Ubiquitinylated TAR DNA-binding protein (TDP-43) accumulates Ubiquilin 2 – involved in transport of ubiquinylated proteins to proteasome FUS protein

46 Amyotrophic lateral sclerosis Ubiquitinylated TAR DNA-binding protein (TDP-43) accumulates

47

48 Parkinson disease Degradation of aplha-synuclein is a crucial question for Parkinson’s disease Ubiquitin proteasomal system is defective in SN affected neurons Autophagy-lysosomal pathway is also affected

49 Parkinson disease (non-monogenic) Dysfunction of the UPS Reduced proteasome activity in the substantia nigra Reduced expression of proteasomal subunits in the subsatntia nigra Reduced proteasome activity and expression of UPS-related proteins in peripheral blood mononuclear cells Altered proteasome function in toxin-based models of PD Altered proteasome function in alpha -synuclein overexpressing rodents Mutated PSMC1 subunit of ATPase in a rodent model

50

51 SKP1A protein interacting E3 ligase is down-regulated in PD Cullin UbE2

52

53

54 Early PD

55 Late PD

56 Enahncement of autophagy by rapamycin (inhibitor of mTOR) is prospective for tratment of neurodeganerative diseases

57 Autoimmune diseases Autonatibodies to proteasomes in Sjogren’ s syndrome SLE Rheumatoid arthritis Autoimmune myositis Result in decreased proteasomal activity

58

59 Inflammatory response

60 Inflammatory disease Inflammatory arthritis. Proteasome inhibition improves the arhritis score. Psoriasis. T-cell mediated disease, related to activation of NF-kappa. Proteasome inhibition reduces lesions.

61 Asthma and allergy Abnormal activation of of Type 2 helper cells. E3 ubiquitin ligase Itch maintains immune tolerance. Itch-deficient mice fail to block development of airway inflamamation.

62 Cell proliferation and cancer

63

64 Proteasomes regulate density of cardiac ion channels Mutations in SCNA5 gene encoding Nav1.5 channel hindering its interactions with E3 (Nedd4-2) cause arrhythmias and conduction defects Mutations in the gene hERG1 (K+ channel) resulting in its rapid decay cause the long QT syndrome

65 Heart diseases Atrophy/ Unloading HypertrophyHypoxemiaHeart failure Ub mRNAIncreased _ E2 mRNAIncreased _

66 Heart diseases 2 Atrophy/ Unloading HypertrophyHypoxemiaHeart failure E3 mRNA Atrogin 1 DecreasedIncreased _ E3 mRNA MuRF1 DecreasedIncreased _

67 Heart diseases 3 Atrophy/ Unloading HypertrophyHypoxemiaHeart failure Proteasome proteolytic Activity Decreased PSMB4 mRNA Increased

68 Heart diseases 4 Atrophy/ Unloading HypertrophyHypoxemiaHeart failure De- ubiquitination enzymes Increased

69 Proteasome inhibitors Cancer treatment Antiinflammatory action

70

71 Funding Joint research project “Genetic studies of human diseases and longevity in Latvian population”, sub-project “Genome-wide scanning of proteasomal gene polymorphisms and their association with autoimmune diseases” - No /09 National Reserach Program /VPP4 „Creation of novel means and methods for prophylaxis, treatment and diagnostics, elaboration of biomedical Technologies for improvement of social health“ ERAF project ESS2010/110 „Creation of a method for early diagnostics of autoimmune diseases” Joint LV-LT-TW project “Proteasomal gene alleles as risk factors for bronchial asthma in Latvian, Lithuanian and Taiwanese populations ”

72 Ieguldījums Jūsu nākotnē


Download ppt "Proteasome-ubiquitin pathway in pathology Nikolajs Sjakste, Faculty of Medicine, University of Latvia Genetic and Environmental Influence of Bronchial."

Similar presentations


Ads by Google